Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Oliver G. Ottmann, Philippe Rousselot, Françoise Huguet et al.|Blood|2018

Cited by 51